本品は獣医師様及び日本税関で止められた際、ご自身で通関手続きが可能な方、もしくは弊社による通関手続き代行料として別途4900円（数量６点まで）をお支払い頂いたお客様のみに発送致します。

（１）獣医師様は、日本税関で止められましても、通関手続きなし（フリーパス）で問題なく商品がお受け取りできます。

（２）獣医師様以外の方は、税関で止められた場合、通関手続きが必要になりますが、手続きをされることでお受け取りが可能です。獣医師様以外のお客様がご自身で税関対応される場合は獣医師様発行の処方箋が必要になります。

（３）獣医師様以外のご自身での税関対応が不可のお客様には手続き代行料として別途4900円（数量６点まで）をお支払い頂きましたら、弊社側で手続き代行し、お手元にお届け致します。

＜備考＞

・(1)、(2)に該当するお客様に関しまして税関対応・通関手続きの具体的な方法は、日本税関で止められた場合にご連絡差し上げます。

・(3)に該当するお客様に関しましてはご注文後、自動送信で送られてくる確認メールに「税関対応依頼」と記載し、返信頂ければ、こちらから改めてご連絡差し上げます。

詳細はこちら→注射液のご注文につきまして。

（商品説明）

副腎皮質ステロイド（メチルプレドニゾロン4%含有。）

自己免疫不全系の様々なアレルギー症状や深刻な関節系、皮膚系、眼性／耳性、腱などの炎症障害に関して長期的で強力な効果を発揮するステロイド注射液。

在庫保有不可能商品ですので、ご注文後、都度ヨーロッパの専門サプライヤー

よりの取り寄せ発送となります。

ご注文頂いてからお手元に届くまで２～３週間ほどかかりますこと、ご了承下さ

い。

＜ヨーロッパ製＞

（使用法）

適量を皮下注射。

投与量や投与回数は、獣医師、専門医と必ず相談の上、ご使用下さい。

（使用期限）

ご注文時より最低１年以上

-------------------------------------------------------------------------------------------------------------------------------------------------------------------

We are going to ship this item only to vets and orderers who go throug costoms if the parcel is stopped by Custom.

（１）Vets can receive this item without any procedure.

（２）Orderes who are not vets need to make customs clearance procedures and they need a prescription issued by a vet.

Depo-Medrone V 40 mg/ml Suspension for Injection 5ml.

Presentation

Each ml contains 40 mg methylprednisolone acetate and 0.2 mg myristyl-gamma-picolinium chloride as preservative.

Uses

Injectable corticosteroid.

For the treatment of, or as part of a therapeutic regime for, inflammatory and allergic conditions in dogs and cats such as: allergic or non-specific inflammatory dermal conditions, musculo-skeletal conditions, ocular/otic inflammatory conditions and other inflammatory/allergic conditions that are likely to respond to corticosteroid therapy e.g. autoimmune disorders.

For the treatment of, or as part of a therapeutic regime for, musculo-skeletal conditions in horses which are not intended for human consumption.

Dosage and administration

The dosage needed may vary according to individual clinical circumstances such as the severity of the condition to be treated, size of animal and clinical response.

The following dosage recommendations are therefore initial guidelines and may need slight alteration in the light of individual response.

An insulin type syringe should be used to measure and administer volumes of less than 1 ml.

Local

Aseptic precautions are important.

Horses

The average initial dose for a large synovial space is 120 mg (3 ml). Smaller spaces will require a correspondingly lesser dose. The intratendinous dose ranges from 80–400 mg (2–10 ml) depending on the size of the tendon.

Dogs and cats

The usual intramuscular dose for dogs and cats is 1–2 mg/kg.

Injections may be repeated in accordance with the severity of the condition and clinical response. Relief from clinical signs is usually sustained for up to three weeks but may range from one to more than four weeks.

For maintenance therapy in chronic conditions, initial doses should be gradually reduced until the smallest effective dose is established.

Contra-indications, warnings, etc

Aseptic injection techniques should be practised. Depo-Medrone V must not be given intravenously. The technique of aspiration should be employed, as appropriate, to avoid intravascular injection. Due to the potential for local cosmetic effects, the subcutaneous use of this product in show animals is not recommended. Intrasynovial, intratendinous or other injections of corticosteroids for local effect are contra-indicated in the presence of acute infectious conditions.

It is recommended that Depo-Medrone V is not mixed with any other product for injection at the same site. Exacerbation of pain, further loss of joint motion, with fever and malaise following intrasynovial injection may indicate that the condition has become septic and appropriate antibacterial therapy should be instituted immediately. Animals receiving corticosteroids should be monitored for signs of infection and, where necessary, appropriate antimicrobial therapy instigated.

As with any corticosteroid, treatment of working or racing animals should be followed by a period of rest to allow resolution of the clinical condition.

It is recommended that, where joint therapy is indicated, a radiologic examination is undertaken prior to treatment to evaluate the presence of fractures. If fractures are present, corticosteroid therapy should only be used with utmost caution if permanent damage is to be avoided.

Anti-inflammatory corticosteroids, such as methylprednisolone, are known to exert a wide range of side-effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long term use and when esters possessing a long duration of action are administered. Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control clinical signs. The continued or prolonged use of this product is not generally recommended.

Steroids themselves, during treatment, may cause Cushingoid symptoms involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, muscle weakness and wastage and osteoporosis may result. During therapy effective doses suppress the Hypothalamo-Pituitary-Adrenal axis. Following cessation of treatment, signs of adrenal insufficiency extending to adrenocorticol atrophy can arise and this may render the animal unable to deal adequately with stressful situations. Consideration should therefore be given to means of minimising problems of adrenal insufficiency following the withdrawal of treatment, e.g. a gradual reduction of dosage (for further discussion see standard texts).

Systemically administered corticosteroids may cause polyuria, polydipsia and polyphagia, particularly during the early stages of therapy. Some corticosteroids may cause sodium and water retention and hypokalaemia in long term use. Locally applied steroids may cause thinning of the skin and systemic corticosteroids have caused deposition of calcium in the skin (calcinosis cutis).

There are risks associated with the use, especially systemically, of corticosteroids during pregnancy. The safety of methylprednisolone in canine, feline and equine pregnancy has not been established. Systemic activity of corticosteroids in early pregnancy is known to have caused foetal abnormalities in laboratory animals and in late pregnancy may cause early parturition or abortion.

Corticosteroids may delay wound healing and the immunosuppressant actions may weaken resistance to or exacerbate existing infections. In the presence of bacterial infection, anti-bacterial drug cover is usually required when steroids are used. In the presence of viral infections, steroids may worsen or hasten the progress of the disease.

Systemic corticosteroid therapy is generally contra-indicated in patients with renal diseases and diabetes mellitus. Gastrointestinal ulceration has been reported in animals treated with corticosteroids and g.i.t. ulceration may be exacerbated by steroids in patients given non-steroidal anti-inflammatory drugs and in corticosteroid treated animals with spinal cord trauma. Steroids may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.

The product is contra-indicated for the treatment of laminitis in horses. Additionally it should be noted that use of the product in horses for other conditions could induce laminitis and careful observations during the treatment period should be made.

During a course of treatment the clinical condition of the animal should be reviewed regularly by close veterinary supervision.

Withdrawal periods

Not to be used in horses intended for human consumption.

Treated horses may never be slaughtered for human consumption.

The horse passport must have been declared as not intended for human consumption under national horse passport legislation.

Operator warnings

Wear protective gloves when using this product. Care must be taken to avoid accidental self-injection. Accidental spillage onto the skin should be washed off immediately with soap and water.

Pharmaceutical precautions

Do not store above 25°C. Do not freeze. Shake vial before use. Following withdrawal of the first dose, the product should be used within 28 days. Any unused product and empty containers should be disposed of in accordance with guidance from your local waste regulation authority.

Keep out of reach and sight of children.

For animal treatment only.

Legal category

Packaging Quantities

Supplied in multidose 5 ml vials.